Characterization of ELISA detection of broad-spectrum anti-Epstein–Barr virus antibodies associated with nasopharyngeal carcinoma

Authors

  • Cindy Chang,

    1. Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, Maryland
    Search for more papers by this author
  • Jaap Middeldorp,

    1. Department of Pathology, Vrije University Medical Center, Amsterdam, The Netherlands
    Search for more papers by this author
  • Kelly J. Yu,

    1. Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, Maryland
    2. Division of Cancer Prevention, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, Maryland
    Search for more papers by this author
  • Hedy Juwana,

    1. Department of Pathology, Vrije University Medical Center, Amsterdam, The Netherlands
    Search for more papers by this author
  • Wan-Lun Hsu,

    1. Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    2. Genomics Research Center, Academia Sinica, Taipei, Taiwan
    Search for more papers by this author
  • Pei-Jen Lou,

    1. Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Search for more papers by this author
  • Cheng-Ping Wang,

    1. Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Search for more papers by this author
  • Jen-Yang Chen,

    1. National Institute of Cancer Research, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan
    Search for more papers by this author
  • Mei-Ying Liu,

    1. Center of General Education, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan
    Search for more papers by this author
  • Ruth M. Pfeiffer,

    1. Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, Maryland
    Search for more papers by this author
  • Chien-Jen Chen,

    1. Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    2. Genomics Research Center, Academia Sinica, Taipei, Taiwan
    Search for more papers by this author
  • Allan Hildesheim PhD

    Corresponding author
    1. Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, Maryland
    • Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd., EPS 7066, Rockville, MD 20892.
    Search for more papers by this author

  • This is a US government work, and, as such, is in the public domain of The United States of America.

Abstract

Epstein–Barr virus (EBV) infection is associated with undifferentiated nasopharyngeal carcinomas (NPC). A distinct seroreactivity pattern to EBV is predictive of subsequent risk of sporadic and familial nasopharyngeal carcinomas. There are currently no accepted screening tools for guiding the clinical management of individuals at high-risk for nasopharyngeal carcinomas, particularly unaffected relatives from nasopharyngeal carcinoma multiplex families. Therefore, the reproducibility of a panel of largely synthetic peptide-based anti-EBV antibody ELISAs was evaluated and their ability to distinguish nasopharyngeal carcinoma cases from controls was explored. IgG and IgA antibodies against 6 different EBV antigens (10 assays, total) were tested on sera from 97 individuals representing the full spectrum of anti-EBV seroprevalence (i.e., healthy individuals with no known EBV seroreactivity, healthy individuals with known EBV seroreactivity, and nasopharyngeal carcinoma cases). Each specimen was tested in triplicate to assess within-batch and across-batch variation, and the triplicate testing was repeated on two separate days. Reproducibility was assessed by the coefficients of variation (CVs) and intraclass correlation coefficients (ICCs). All markers were detectable in 17% or more of samples. For all but one marker, the overall, within-batch, and across-batch CVs were below 15%, and the ICCs were above 70% for all but three markers. Sensitivity of these markers to detect prevalent nasopharyngeal carcinomas ranged from 22% to 100%, and among unaffected controls, most distinguished those with and without known seropositivity. In conclusion, a large number of EBV markers can be measured reliably in serum samples using peptide-based anti-EBV ELISAs. J. Med. Virol. 85:524–529, 2013. Puiblished 2012. This is a US government work, and, as such, is in the public domain of The United States of America.

Ancillary